Why the study?
Do various lifestyle, pharmacological, and procedural therapeutic modifications improve arterial stiffness in patients at high cardiovascular risk?
Do various lifestyle, pharmacological, and procedural therapeutic modifications improve arterial stiffness in patients at high cardiovascular risk?
This comprehensive review highlights that arterial stiffness, a marker of cardiovascular disease, can be improved through various lifestyle, pharmacological, and procedural interventions tailored to specific patient populations.
Answers are grounded in this paper and cite their sources.
Multimodal risk factor modification may improve arterial stiffness; leaves open effects on clinical outcomes pending prospective trials.
Arterial stiffness has been recognized as a marker of cardiovascular disease and associated with long-term worse clinical outcomes in several populations. Age, hypertension, smoking, and dyslipidemia, known as traditional vascular risk factors, as well as diabetes, obesity, and systemic inflammation lead to both atherosclerosis and arterial stiffness. Targeting multiple modifiable risk factors has become the main therapeutic strategy to improve arterial stiffness in patients at high cardiovascular risk. Additionally to life style modifications, long-term ω-3 fatty acids (fish oil) supplementation in diet may improve arterial stiffness in the population with hypertension or metabolic syndrome. Pharmacological treatment such as renin-angiotensin-aldosterone system antagonists, metformin, and 3-hydroxy-3-methyl-glutaryl-CoA reductase inhibitors were useful in individuals with hypertension and diabetes. In obese population with obstructive sleep apnea, weight reduction, aerobic exercise, and continuous positive airway pressure treatment may also improve arterial stiffness. In the populations with chronic inflammatory disease such as rheumatoid arthritis, a use of antibodies against tumor necrosis factor-alpha could work effectively. Other therapeutic options such as renal sympathetic nerve denervation for patients with resistant hypertension are investigated in many ongoing clinical trials. Therefore our comprehensive review provides knowledge in detail regarding many aspects of pathogenesis, measurement, and management of arterial stiffness in several populations, which would be helpful for physicians to make clinical decision.
No takes yet. Share an insight, caveat, or question.
Ching-Fen Wu (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: